CN1457775A - Composition containing dihydro myricitrin and myricitrin - Google Patents
Composition containing dihydro myricitrin and myricitrin Download PDFInfo
- Publication number
- CN1457775A CN1457775A CN03138054A CN03138054A CN1457775A CN 1457775 A CN1457775 A CN 1457775A CN 03138054 A CN03138054 A CN 03138054A CN 03138054 A CN03138054 A CN 03138054A CN 1457775 A CN1457775 A CN 1457775A
- Authority
- CN
- China
- Prior art keywords
- compositions
- ampelopsin
- dihydromyricetin
- group
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of composition containing dihydro myricitrin in 20-98 wt% and myricitrin in 2-80 wt%. The said composition also contains one or several of the following components: populoside, gallic acid and tea polyphenol. The composition has wide application in the field of preparing medicine and health articles. The preparation process of the composition is also disclosed.
Description
Invention field
The invention belongs to natural drug and field of health care products.
Background of invention
Document Walter Karrerr, Birkhauser Verlag, Bassel undstuttgart (1958), P.652, NO:1640 discloses the structural formula of dihydromyricetin,
But the activity of dihydromyricetin is not studied.Ampelopsin is a kind of compound known, and its structural formula is:
Nobody disclosed the composition and use thereof that contains dihydromyricetin and ampelopsin up to now.
Detailed description of the present invention
The purpose of this invention is to provide a kind of new compositions, it contains dihydromyricetin and ampelopsin, and wherein the dihydromyricetin cellulose content is 20% to 98% weight ratio, and ampelopsin content is 2% to 80% weight ratio.Can also contain one or more in the present composition and be selected from following composition: arbutin, gallic acid and/or tea polyphenols.The content of arbutin preferably accounts for the 0-50wt% of dihydromyricetin and ampelopsin gross weight, the content of gallic acid preferably accounts for the 0-50wt% of dihydromyricetin and ampelopsin gross weight, and the content of tea polyphenols preferably accounts for the 0-50wt% of dihydromyricetin and ampelopsin gross weight.
The applicant is surprisingly found out that the compositions that contains dihydromyricetin and ampelopsin has purposes widely at pharmaceutical field and field of health care products.
The compositions that contains dihydromyricetin and ampelopsin of the present invention has hypoglycemic activity, can be prepared into blood sugar lowering.The compositions itself that contains dihydromyricetin and ampelopsin of the present invention can be directly medicinal, also can be mixed with pharmaceutical composition by conventional preparation technique of drug world and carrier.The present composition can be prepared into tablet, granule, capsule, medicine for external use.But those skilled in the art also can be mixed with other dosage form with technology well known in the art and carrier as required.The dosage that preferred active component is used the people is 0.01-5 gram/kg body weight/sky, but also can decide as the case may be, is not limited to this scope.
The compositions that contains dihydromyricetin and ampelopsin of the present invention also has prevention and/or recovers the function of alcoholic liver injury, can be used as additive is added in various types of wine, itself and wine are complementary, and can not change original colourity and the clarity and the sense of taste of wine.Wine comprises ethanol wine and wine.The content that contains the compositions of dihydromyricetin and ampelopsin in the wine can be 0.5-53%w/v (percent weight in volume (grams per liter), hereinafter identical), preferably 2%w/v is to the amount of the degree of dissolution saturation of the compositions that contains dihydromyricetin and ampelopsin in various wine.Can be directly the compositions that contains dihydromyricetin and ampelopsin of described amount be added in the wine and stirs, make the compositions that contains dihydromyricetin and ampelopsin wine as additive.
The compositions that contains dihydromyricetin and ampelopsin of the present invention can also be used as food additive, as a kind of all kinds of staple foods such as making various steamed breads, sweet dumplings, cake, fritters of twisted dough, noodles, cake, cake, cookies, bread, rice, ham sausage of preparing burden, become food, prepare various health foods and beverage as a kind of various liquid such as making beverage with various different tastes, popsicle, ice cream of preparing burden.The addition 0.5%-45wt% of food gross weight preferably that contains the compositions of dihydromyricetin and ampelopsin.
Another object of the present invention provides the method for compositions that preparation the present invention contains dihydromyricetin and ampelopsin.Compositions of the present invention can also can be extracted from ampelopsis by described constituent monomers is mixed in proportion preparation.Described ampelopsis comprises ampelopsis cantoniensis, a leaf beautiful Fructus Vitis viniferae, Ampelopsis grossedentata, Cayratia japonica (Thunb.) Gagnep., Radix Ampelopsis, Northeastern Caulis seu folium ampelopsis brevipedunculatae and Vitis Amurensis.Described extracting method can be: decoct vitaceae by all kinds of solvents (water and/or organic solvent), decoct one or many, decoction liquor is through concentrating cooling, standing over night, detection precipitates the active ingredient with supernatant, gets to have active precipitation and/or obtain the present composition after further silica gel adsorption.Decoct used solvent preferred water, alcohols, esters, ketone, ethers and strong polar organic solvent, more preferably low-level chain triacontanol, low-grade fatty acid ester has ketone and ether and/or water, the most preferably methanol of 3-12 carbon atom, ethanol, propanol, isopropyl alcohol, n-butyl alcohol, isobutanol, sec-butyl alcohol, the tert-butyl alcohol, ethyl acetate, methyl acetate, Ethyl formate, acetone, methyl ethyl ketone, ether, methyl ethyl ether, methyl tertiary butyl ether(MTBE), dichloromethane, chloroform, carbon tetrachloride, dimethyl sulfoxine, N, dinethylformamide and/or water or the like.Separating the adsorbent that uses can be silica gel.
The compositions that contains dihydromyricetin and ampelopsin of the present invention can be used for preparing hypoglycemic drug, can also be added in various types of wine as additive, makes health promoting wine and health food and non-alcoholic beverage.
Describe the present invention in detail by the following examples.But should be appreciated that these embodiment just illustrate the present invention, rather than in office where face limits the scope of the invention.Embodiment 1: prepare the present composition from dihydromyricetin and ampelopsin crystal
Get dihydromyricetin 80g, ampelopsin 20g gets mixture after said components is mixed in mixer.Perhaps get dihydromyricetin 98g, ampelopsin 2g gets mixture after said components is mixed in mixer.Perhaps get dihydromyricetin 20g, ampelopsin 80g gets mixture after said components is mixed in mixer.Embodiment 2: prepare the present composition from dihydromyricetin and ampelopsin crystal
Get dihydromyricetin 20g, ampelopsin 80g, arbutin 2.5g, gallic acid 2.5g, tea polyphenols 2.5g, said components in mixer, mix mixture.Perhaps get dihydromyricetin 98g, ampelopsin 2g, arbutin 2.5g, gallic acid 2.5g, tea polyphenols 2.5g, said components in mixer, mix mixture.Perhaps get dihydromyricetin 85g, ampelopsin 15g, arbutin 25g, gallic acid 2g, said components in mixer, mix mixture.Perhaps get dihydromyricetin 50g, ampelopsin 50g, arbutin 25g, tea polyphenols 2.5g, said components in mixer, mix mixture.Perhaps get dihydromyricetin 70g, ampelopsin 30g, arbutin 5g, said components in mixer, mix mixture.Embodiment 3: prepare the present composition from dihydromyricetin and ampelopsin crystal
Get first kind of compositions (or the third compositions of embodiment 2) 30g of embodiment 1 respectively, lactose 53g, sodium carboxymethyl cellulose 1.5g, magnesium stearate 0.5g, 50% ethanol 5ml, said components is mixed the back compacting in flakes in mixer.Embodiment 4: prepare the present composition from dihydromyricetin and ampelopsin crystal
Get dihydromyricetin 115g, ampelopsin 15g, Icing Sugar 345g, dextrin 145g, ethanol 5ml, said components is mixed after drying, obtains electuary.Embodiment 5: prepare the present composition from porcelain ampelopsis
Get the dry young stem and leaf 2kg of Ampelopsis grossedentata, with 95% ethanol (medical ethanol) reflux, extract, twice, each 2 hours, filter, merging filtrate is evaporated to dried, add 1200 milliliters of 85 ℃ of hot water, extractum is fully dissolved, elimination black insoluble matter, add silica gel (100 order) 200g in the filtrate, filtrate is heated to 60 ℃, take advantage of heat filtering, filtrate is cooled to room temperature, precipitation, standing over night, obtain yellow mercury oxide, productive rate: 11.2%.Dihydromyricetin cellulose content 74.8% weight ratio wherein, ampelopsin content 21.1% weight ratio, the content of arbutin is 2.8% weight ratio, the content of gallic acid is 1.3% weight ratio.Thin-layer chromatographic analysis polyamide thin layer chromatography, specification 8 * 8cm, developing solvent: methanol, developer: 4% ferric chloride-alcoholic solution, R
The f gallic acid=0.72, R
The f arbutin=0.54, R
The f dihydromyricetin=0.50, R
The f ampelopsin=0.21.
Perhaps get the dry young stem and leaf 2kg of Ampelopsis grossedentata, with 95% ethanol (medical ethanol) reflux, extract, twice, each 2 hours, filter, merging filtrate is evaporated to dried, add 1200 milliliters of 85 ℃ of hot water, extractum is fully dissolved, elimination black insoluble matter, filtrate is used twice of equal-volume ethyl acetate extraction, combined ethyl acetate solution, be evaporated to driedly, obtain yellow mercury oxide, productive rate: 10.25%.Dihydromyricetin cellulose content 76% weight ratio wherein, ampelopsin content 18% weight ratio, the content of arbutin is 3.0% weight ratio, and the content of gallic acid is 2% weight ratio, and all the other are R in the porcelain ampelopsis
F5=0.41 composition.Thin-layer chromatographic analysis polyamide thin layer chromatography, specification 8 * 8cm, developing solvent: methanol, developer: 4% ferric chloride-alcoholic solution, R
The f gallic acid=0.72, R
The f arbutin=0.54, R
The f dihydromyricetin=0.50, R
The f ampelopsin=0.21, R
F5=0.41.Embodiment 6: prepare the present composition from the Northeastern Caulis seu folium ampelopsis brevipedunculatae plant
Under the room temperature, the Northeastern Caulis seu folium ampelopsis brevipedunculatae 1000 gram flush away dust with collecting add 4000 ml waters, supersound extraction 0.5 hour is filtered, and residue adds 1000 milliliters of propanol again, supersound extraction is 0.5 hour again, refilters, and filtrate merges, be concentrated into 2 milliliters, add 500 milliliters of 100 ℃ of hot water, be cooled to 60 ℃, leave standstill, filter.Filtrate is heated to 70 ℃ with silica gel (100 order) 100g absorption with filtrate, takes advantage of heat filtering, and filtrate is cooled to room temperature, precipitation, and standing over night obtains yellow mercury oxide, productive rate: 10.3%.Dihydromyricetin cellulose content 58% weight ratio wherein, ampelopsin content 14% weight ratio, the content of arbutin is 1.4% weight ratio, and the content of gallic acid is 1.7% weight ratio, and all the other are R in the Northeastern Caulis seu folium ampelopsis brevipedunculatae plant
F5=0.43 composition.Thin-layer chromatographic analysis polyamide thin layer chromatography, specification 8 * 8cm, developing solvent: methanol, developer: 4% ferric chloride-alcoholic solution, R
The f gallic acid=0.76, R
The f arbutin=0.55, R
The f dihydromyricetin=0.54, R
The f ampelopsin=0.22, R
F5=0.43.Embodiment 7: the hypoglycemic test 1. materials and methods 1.1. of compositions that contain dihydromyricetin and ampelopsin of the present invention are tried thing: first kind of compositions 1.2. experimental animal that embodiment 5 obtains and testing conditions
Select the female Kunming mouse of healthy cleaning level for use, body weight 24 ± 2g, animal feed operative norm GB14924-94.Sense environmental conditions, temperature range 20-25 ℃, relative humidity scope 40-70%.1.3. dosage is selected
Test divides intact animal and two batches of hyperglycemia model animals to carry out, and respectively establishes 1 matched group (distilled water) and is tried thing 0.25,0.50,1.50g/kg dosage group, is equivalent to 5,10 and 30 times of people's recommended intake respectively, irritates the stomach amount and is 0.1ml/10g.1.4. key instrument and reagent
Alloxan (Alloxan): Sigma company; 50% glucose injection: new Cao in Yancheng pharmaceutical factory.
The super blood sugar detection instrument of SUPER GLUCOCARD II GT-1640 type: Japanese capital person first science Co., Ltd. produces: the GLUCOCARD blood sugar test paper: Japanese capital person first science Co., Ltd. produces.1.5. experimental technique 1.5.1. intact animal: fasting was got mice and is surveyed blood glucose after 5 hours.40 of the mice of screening fasting glucose in normal range, be divided into four groups at random by blood sugar level, every group 10, be respectively each dosage group of normal control group and sample (difference is not more than 1.1mmol/L between group) " 1.5.2. hyperglycemia model animal: strict fasting is after 24 hours, mouse tail vein injection alloxan 50mg/kgBW, fasting is 5 hours after 6 days, surveys blood glucose.The mice 40 of screening fasting blood sugar＞10mmol/L is done, and is divided into four groups at random by blood sugar level, 10 every group, is respectively each dosage group of model control group and sample (difference is not more than 1.1mmol/L between group).1.5.3. the mensuration of fasting glucose and carbohydrate tolerance: by design dosage mice continuous irrigation stomach was tried thing 30 days, fasting is 5 hours then, gives glucose 1.5g/kgBW and irritates stomach, measures blood glucose value respectively in 0,0.5,2.0 hour 3 phase.1.6. statistical method
All experimental data adopts SPSS/PC software kit (one factor analysis of variance) to handle on microcomputer.2. 2.1. contains the influence of the compositions of dihydromyricetin and ampelopsin to the normal mouse body weight as a result
Table 1 respectively organize normal mouse initial body weight, mid-term body weight, finish the initial body weight of body weight group body weight in mid-term and finish body weight
Number of animals body weight (g) number of animals body weight (g) number of animals body weight (g) normal control 10 23.4 ± 1.0 10 30.5 ± 1.5 10 32.4 ± 1.6 is subjected to 0.25g/kg 10 23.7 ± 1.0 10 31.3 ± 1.3 10 33.0 ± 1.7 examination 0.50g/kg 10 23.6 ± 1.1 10 30.8 ± 1.7 10 32.2 ± 1.8 thing 1.50g/kg 10 23.6 ± 1.3 10 31.0 ± 1.4 10 33.7 ± 17F value, 0.115 0.475 0.353P values, 0.951 0.701 0.787 notes: each dosage group Mouse Weight of tested material compared in each experimental period and Normal group; The equal nonsignificance of difference (variance analysis, P＞0.05) 2.2. contains the composition of dibydro myricetrin and myricetin to the impact of normal mouse fasting blood-glucose
Table 2 contains the influence of the compositions of dihydromyricetin and ampelopsin to the normal mouse fasting glucose
| Group | Number of animals (only) | Fasting blood sugar (mmol/L) | Difference | |
| After testing before the test | ||||
| Tried thing | Normal control 0.25g/kg 0.50g/kg 1.50g/kg | ??10 ??10 ??10 ??10 | ????4.7±0.5????4.6±0.7 ????4.4±0.7????4.3±0.8 ????4.6±0.9????4.4±0.9 ????4.5±0.8????4.5±0.8 | ??0.1±06 ??0.1±1.2 ??0.2±1.0 ??0.0±0.5 |
F value 0.388 0.302 0.099
P value 0.762 0.82 0.960 is annotated: tried each dosage group fasting blood sugar of thing and normal control group relatively, difference there are no significant meaning (variance analysis, P＞0.05).2.3. contain of the influence of the compositions of dihydromyricetin and ampelopsin to the normal mouse post-prandial glycemia
The compositions that table 3 contains dihydromyricetin and ampelopsin influences group number of animals glucose 0h blood glucose value (mmol/L) to the normal mouse post-prandial glycemia
(only) (g/kgBW) 0.5h 2h normal control 10 1.5 4.6 ± 0.7 10.4 ± 1.2 5.5 ± 0.7 is subjected to 0.25g/kg 10 1.5 4.3 ± 0.8 10.8 ± 1.0 5.2 ± 1.0 examination 0.50g/kg 10 1.5 4.4 ± 0.9 10.5 ± 1.6 5.0 ± 1.2 thing 1.50g/kg 10 1.5 4.5 ± 0.8 10.5 ± 1.4 5.2 ± 1.9F value, 0.302 0.230 0.529P values, 0.824 0.875 0.665 notes: each dosage group postprandial plasma glucose level of tested material and Normal group are relatively; Difference there are no significant meaning (variance analysis, P＞0.05). 2.4. contain of the influence of the compositions of dihydromyricetin and ampelopsin to the normal mouse carbohydrate tolerance
The compositions that table 4 contains dihydromyricetin and ampelopsin influences group number of animals blood sugar increasing and reduction amplitude (mmol/L) to the normal mouse carbohydrate tolerance
(only) 0.5h-0h 0.5h-2h normal control 10 5.8 ± 0.9 4.8 ± 0.9 is tried 0.25g/kg 10 6.5 ± 0.6 5.6 ± 1.2 thing 0.50g/kg 10 6.1 ± 1.0 5.5 ± 1.0
1.50g/kg 10 6.0 ± 1.4 5.3 ± 1.3F value, 0.998 1.018P value 0.405 0.396 is annotated: tried each dosage group carbohydrate tolerance value of thing and normal control group relatively, difference there are no significant meaning (variance analysis, P＞0.05).2.5. the compositions that contains dihydromyricetin and ampelopsin is to the influence of the hyperglycemia mice body weight that causes
Table 5 respectively organize the hyperglycemia model mice initial body weight, mid-term body weight, finish the initial body weight of body weight group body weight in mid-term and finish body weight
The number of animals body weight, (g) number of animals body weight, (g) number of animals body weight, (g) normal control 10 24.3 ± 1.3 10 30.7 ± 2.0 10 31.2 ± 1.9 are subjected to 0.25g/kg 10 24.5 ± 2.7 10 31.8 ± 2.2 10 32.4 ± 2.8 examination 0.50g/kg 10 24.0 ± 1.4 10 31.7 ± 2.9 10 32.6 ± 2.9 thing 1.50g/kg 10 23.8 ± 1.5 10 30.9 ± 1.9 10 30.8 ± 1.7F value, 0.271 0.576 1.418P values, 0.846 0.634 0.253 notes: each stage body weight of each dosage group of tested material and model control group are relatively; Difference there are no significant meaning (variance analysis, P＞0.05). 2.6. the compositions that contains dihydromyricetin and ampelopsin is to the influence of the hyperglycemia mice fasting glucose that causes
Table 6 contains the shadow of the compositions of dihydromyricetin and ampelopsin to hyperglycemia model mice fasting glucose
Ring
| Group | Number of animals (only) | Fasting blood sugar (mmol/L) | Difference | |
| After testing before the test | ||||
| Tried | Normal control 0.25g/kg 0.50g/kg | 10 10 10 | ????22.9±3.3????20.4±5.1 ????22.9±3.0????13.2±4.1* ????22.4±2.5????15.3±6.4 | ????2.5±4.2 ????9.7±3.7* ????7.2±4.7 |
1.50g/kg????????????????10?????????22.5±3.5???????17.1±6.3????????5.4±6.1
F value 0.068 3.058 4.137
P value 0.977 0.041 0.0123 is annotated: compare * P＞0.05 (q check) with model control group
Tried thing low dose group test back fasting blood sugar and front and back fasting glucose difference and model control group relatively, difference all has significantly (variance analysis, P＞0.05).2.7. the compositions that contains dihydromyricetin and ampelopsin is to the influence of the hyperglycemia mice post-prandial glycemia that causes
The compositions that table 7 contains dioxy ampelopsin and ampelopsin influences group number of animals glucose 0h blood glucose value (mmol/L) to hyperglycemia type mice post-prandial glycemia
(only), (g/kgBW) 0.5h 2h normally is subjected to 0.25g/kg 10 1.5 13.2 ± 4.1* 26.4 ± 4.2 16.5 ± 6.6* to try 0.50g/kg 10 1.5 15.3 ± 6.4 27.1 ± 5.7 16.9 ± 7.2* thing 1.50g/kg, 10 1.5 17.1 ± 6.3 28.4 ± 4.3 20.2 ± 7.2F value, 3.058 2.393 3.536P values, 0.041 0.085 0.024 notes to 10 1.5 20.4 ± 5.1 31.2 ± 2.7 24.7 ± 3.7: the low agent group of tested material after the meal 0h blood glucose value compares with low middle dosage group 2h-plasma glucose value and model control group; Difference all has significantly (variance analysis, P＞0.05). 2.8. the compositions that contains dihydromyricetin and ampelopsin is to the influence of the hyperglycemia mice carbohydrate tolerance that causes
The compositions that table 8 contains dihydromyricetin and ampelopsin influences group number of animals blood sugar increasing and reduction amplitude (mmol/L) to hyperglycemia model mice carbohydrate tolerance
(only)
0.5h-0h 0.25g/kg 10 13.3 ± 1.7 9.9 ± 3.0 thing 0.50g/kg 10 11.8 ± 3.6 10.1 ± 3.7 are tried in 0.5h-2h normal control 10 10.8 ± 3.2 6.5 ± 2.9
1.50g/kg 10 11.3 ± 2.9 8.3 ± 4F value, 1.301 2.255P values 0.289 0.099 are annotated: tried each dosage group carbohydrate tolerance value of thing and model control group relatively, difference all has significantly (variance analysis, P＞0.05).
Experimental result shows that the compositions that contains dihydromyricetin and ampelopsin has the blood sugar regulation effect.
Carry out identical test with the second kind of compositions of the third compositions of first kind of compositions of embodiment 1, embodiment 2, embodiment 5 or the compositions of embodiment 6, obtained roughly the same result.Embodiment 8: the test that contains the compositions blood fat reducing of dihydromyricetin and ampelopsin of the present invention
Animal is divided into 4 groups at random, normal control group, positive controls, model control group, extracting solution group.Every group of 10 mices, once-a-day, successive administration 10 days, the normal control group is not given any medicine.All the other all to high lipoprotein emulsion 0.5ml/ only respectively organize mice, form experimental hyperlipidemia, overnight fasting after medication in 10 days, press enzyme process and detect serum total cholesterol (TC), triglyceride (TG), HDL-C (HDL-C) content from the mouse orbit extracting vein blood next day.The result shows, model control group serum TC, TG value obviously raise, the HDL-C value descends, compare with model, first kind of compositions group of embodiment 5 can obviously reduce serum TC, TG value, HDL-C is slightly raise, illustrate that this extract can suppress the mice blood fat rising that high lipoprotein emulsion causes, has effect for reducing fat.Carry out identical test with the second kind of compositions of the third compositions of first kind of compositions of embodiment 1, embodiment 2, embodiment 5 or the compositions of embodiment 6, obtain identical result.1. material and method 1.1. are tried thing: first kind of compositions that embodiment 5 obtains is for experiment with the turbid solution that distilled water is mixed with desired concn trying thing.1.2. laboratory animal: SPF level Wistar rat, body weight 170-190g, female, totally 55 (5 are standby).Experimental temperature: 23-25 ℃, relative humidity: 65-70%.1.3. the common normal feedstuff of feedstuff: 1.3.1.: prescription slightly.(the pure Mus material of the Wistar of Hubei Province Preventive Medicine Academy's Experimental Animal Center preparation).1.4. the dosage grouping: experiment is divided into five groups, be normal control group, hyperlipidemia model matched group and tried basic, normal, high three the dosage groups of thing, dosage is respectively 0.5,1.0,1.5g/kg.bw, is equivalent to manufacturer and recommends 10,20,30 times of human body daily intaking amount 3g/60kg.bw.1.5. experimental technique:
The rat adaptability is raised and is begun experiment after 3 days.Get rat tail blood, measure serum total cholesterol (TC0), triglyceride (TG0), HDL-C (HDL-c0) basic value.According to the TC0 level, rat is divided into five groups at random, every group of 10 animals, promptly basic, normal, high dosage group, normal control group and hyperlipidemia model matched group.Except that the normal control group gives the normal feedstuff, all the other each groups all give high lipid food.Three are tried agent amount group and irritate stomach by the capacity per os of 1.0ml/100g.bw and give, the feed of freely drinking water of normal control group and hyperlipidemia model matched group.Give 30 days continuously, detected TC, TG, HDL-C value on the 30th day in irritating stomach.1.6. key instrument and reagent: SABA-18 type automatic clinical chemistry analyzer (Italy produces), standard quality controlled serum and corresponding reagent box are produced by Shanghai Foxing Changzheng medical science Co., Ltd.1.7. date processing: adopt the STATA statistical software carry out statistical analysis 2. as a result first kind of compositions of 2.1. to the influence of hyperlipidemia model the weight of animals: as seen from Table 9, compare with model control group, basic, normal, high dosage group around the time rat body weight all be lower than model control group, basic, normal, high dosage group and model control group comparing difference have significance (P＜0.01, P＜0.01, P＜0.01).With the normal control group relatively, body weight all is higher than the normal control group around the basic, normal, high dosage group the, but credit is analysed by statistics, difference does not have significance.
Table 9 contains the compositions of dihydromyricetin and ampelopsin
To the influence of high blood lipid model rat body weight (g, x ± s)
Dosage number of animals body weight
The 3rd week of second week first week of g/kg.bw (only) starting weight is heavy eventually
Normal control 10 181.4 ± 2.8 202.2 ± 6.2 219.6 ± 4.7 226.2 ± 3.7 230.7 ± 4.0**
Model contrasts 10 181.7 ± 3.5 208.7 ± 2.6 224.5 ± 4.4 231.4 ± 3.5 237.6 ± 3.7
0.5???????????10?????????182.4±4.1???????208.1±2.6???????221.7±3.4???????227.9±3.4???????233.6±3.0**
1.0???????????10?????????183.1±2.8???????207.0±2.5???????221.5±2.4???????227.7±2.0???????233.2±2.1**
1.5???????????10?????????182.3±2.5???????208.3±2.8???????220.3±3.2???????226.2±3.8???????232.7±3.1**
* and model control group compare the influence of first kind of compositions of P＜0.012.2. to the rat total cholesterol level: as seen from Table 10, compare with model control group, middle and high dosage group total cholesterol level descended obviously at experimental session when experiment finished, credit is analysed by statistics, and difference has significance (p＜0.05, P＜0.01).
Table 10 contains the compositions of dihydromyricetin and ampelopsin
To the influence of rat total cholesterol level (mmol/L, x ± s)
Dosage number of animals T-CHOL
P value test back P value before g/kg.bw (only) test
Normal control 10 1.80 ± 0.07 0.786 1.81 ± 0.16 0.000
Model contrasts 10 1.81 ± 0.11-3.72 ± 0.34-
0.5?????????????10??????1.83±0.10???????0.803????3.35±0.55?????0.269
1.0?????????????10??????1.82±0.10???????0.928????3.10±0.54*????0.010
1.5?????????????10??????1.84±0.11???????0.634????2.86±0.57**???0.001
* compare P＜0.05 with model control group, * and model control group compare the influence of first kind of compositions of P＜0.012.3. to the rat content of triglyceride: as seen from Table 11, compare with model control group, basic, normal, high dosage group content of triglyceride descends obviously during off-test, credit is analysed by statistics, and difference has significance (P＜0.05, P＜0.01, P＜0.01).
Table 11 contains the compositions of dihydromyricetin and ampelopsin
To the influence of rat content of triglyceride (mmol/L, x ± s)
Dosage number of animals T-CHOL
P value test back P value before g/kg.bw (only) test
Normal control 10 1.24 ± 0.25 0.828 1.29 ± 0.11 0.000
Model contrasts 10 1.26 ± 0.27-2.30 ± 0.47-
0.5????????????10??????1.23±0.19???????0.788????????1.90±0.29*?????0.011
1.0????????????10??????1.24±0.18???????0.820????????1.89±0.24**????0.009
1.5???????????10???????????1.21±0.15??????0.584??????????1.86±0.12**???????0.008
* compare P＜0.05 with model control group, * and model control group compare the influence of P＜0.012.4. compositions to rat HDL-C content: as seen from Table 12, compare with model control group, basic, normal, high dosage group has the rising effect to HDL-C, credit is analysed by statistics, and difference has significance (P＜0.05).
Table 12 contains the compositions of dihydromyricetin and ampelopsin
To the influence of rat HDL-C content (mmol/L, x ± s)
Dosage number of animals HDL-C
P value test back P value before g/kg.bw (only) test
Normal control 10 1.13 ± 0.12 0.872 1.06 ± 0.11 0.000
Model contrasts 10 1.12 ± 0.18-0.84 ± 0.11-
0.5?????????????10??????1.10±0.08????0.644????0.94±0.10*????0.027
1.0?????????????10??????1.13±0.09????0.841????0.93±0.07*????0.042
1.5?????????????10??????1.14±0.05????0.733????0.95±0.08*????0.015
* with model control group relatively first kind of compositions of P＜0.052.5. to the influence of rat fat level: this experimental technique is a high lipid food and tried thing and give simultaneously, belongs to preventative, so TG, TC decline and HDL-c rising value all with the comparison of hyperlipidemia model matched group.By table 13 as seen, middle and high dosage group total cholesterol level fall is respectively 16.7%, 23.1%, basic, normal, high dosage group content of triglyceride fall is respectively 17.4%, 17.8%, 19.1%, and basic, normal, high dosage group HDL-C content lift-off value is 4.64,5.03,4.26mg/dl.
Table 13 contains the influence of the compositions of dioxy ampelopsin and ampelopsin to the rat fat level
Dosage number of animals TC TG HDL-C
(%) (%) (mg/dl) for g/kg.bw (only)
0.5????????????10????????????10.3????????17.4??????????4.64
1.0????????????10????????????16.7????????17.8??????????5.03
1.5????????????10????????????23.1????????19.1??????????4.26
Criterion:＞10% decline＞15% rising 4mg/dl descends
Annotate: to be mmol/L * 38.7=mg/dl conversion result carry out identical test with the compositions of the second kind of compositions of the third compositions of first kind of compositions of embodiment 1, embodiment 2, embodiment 5 or embodiment 6 to HDL-c lift-off value (mg/dl), obtained roughly the same result.Embodiment 9: the present invention contains the compositions prevention of dihydromyricetin and ampelopsin and/or recovers function 1, materials and methods 1.1 test products of alcoholic liver injury: the present invention contains the compositions of dihydromyricetin and ampelopsin, sees first kind of compositions of embodiment 5.1.2 laboratory animal: bull mice (18-22 gram), 10 every group.1.3 experimental technique and the grouping of step 1.3.1 dosage and given the test agent give the time
Experiment is established blank group, model control group and is subjected to three dosage groups of test product (to be respectively 10mg/kg, 20mg/kg, 40mg/kg, prepare with dehydrated alcohol respectively, concentration is respectively 0.5mg/ml, 1.0mg/ml, 2.0mg/ml), cause liver injury model with dehydrated alcohol (analytical pure), dehydrated alcohol concentration is 50% (with distilled water diluting), mouse stomach 12-14ml/kgBW (amounting to alcoholic acid dosage is 6000-7000mg/kg BW).It is 30 days that given the test agent gives the time.1.3.2 give the approach of given the test agent
Per os is irritated stomach and is given given the test agent, and writes down feedstuff intake or the amount of drinking water of every animal.1.3.3 experimental procedure
Be subjected to three dosage groups of test product per os every day to irritate the alcoholic solution 0.2ml that stomach gives given the test agent, blank group and model control group give distilled water.Animal is weighed weekly twice.When giving given the test agent and finishing model control group and each sample sets are once irritated stomach and give 50% ethanol 12ml/kg BW, the blank group is given distilled water, and fasting was put to death animal in 15 hours, carried out the detection and the histopathologic examination of every index.1.3.4 detection index
Malonaldehyde in the hepatic tissue (MDA) reduced glutathion (GSH)
Lipid peroxide catabolite malonaldehyde (MDA) assay method 1.4.1 principle in content 1.4 liver homogenate of triglyceride (TG)
MDA (malondiadehycle) is one of snperoxiaized end-product of cell membrane lipid, but detect the degree of its content indirect Estimation lipid peroxidation, MDA and thiobarbituricacid are warm altogether under acid condition, form pink, absworption peak is at 535nm, and this can record the content of MDA tool.1.4.2 instrument and reagent
Instrument product 721 spectrophotometers, micro sample-adding product, thermostat water bath, generic centrifuge, DL device, tool plug centrifuge tube, Potter-Elvehjem Tissue Grinders
Reagent 0.2M acetate buffer PH3.5
0.2M acetic acid solution 185ml
0.2M sodium acetate solution 15ml
1mmol/L tetraethoxypropane (stock solution was preserved 3 months for 4 ℃) faces with before being diluted with water to 40nmol/ml
8.1% sodium lauryl sulphate SDS
0.8% thiobarbituricacid TBA
0.2M phosphate buffer PH7.4
0.2M sodium hydrogen phosphate 1920ml
0.2M potassium dihydrogen phosphate 480ml1.4.3 experimental procedure 1.4.3.1 sample preparation
Tissue homogenate sample: get a certain amount of required internal organs, normal saline flushing, wipe away dried, weigh, shred, put in the homogenizer, add the 0.2M phosphate buffer, spare 10s with 2000r/min, intermittently 30s, carry out repeatedly 3 times, it is even with (W/V) to make 5% tissue, the centrifugal 5 ~ 10min of 3000r/min, and it is to be measured to get supernatant.1.4.3.2 sample determination
Table 14 reagent blank pipe sample cell standard pipe 5% tissue homogenate 0.1ml40nmol/ml tetraethoxypropane 0.1ml8.1%SDS 0.2ml 0.2ml 0.2ml0.2M acetate buffer 1.5ml 1.5ml 1.5ml0.8%TBA 1.5ml 1.5ml 1.5mlH2O 0.8ml 0.7ml 0.7ml mixing, lucifuge boiling water bath 60min, the flowing water cooling is calculated in 532nm colorimetric 1.4.3.3
A: blank pipe absorbance B: the glimmering absorbance F of sample: tetraethoxypropane absorbance C: tetraethoxypropane concentration K: extension rate 1.4.3.4 date processing and result judge
The The data variance analysis, but need to carry out homogeneity test of variance earlier by the program of variance analysis, variance is neat, calculates the F value, F value/F0.05, and conclusion: each organizes the mean differences does not have significance; F value 〉=F0.05, P≤0.05 is added up with the comparative approach in twos of a plurality of experimental grouies and a matched group mean; The data of abnormal or heterogeneity of variance are carried out the conversion of suitable variable, wait to satisfy normal state or variance are neat require after, add up with the data after changing; If do not reach normal state or the neat purpose of variance yet after the variable conversion, use rank test instead and add up.The result judges
Under the prerequisite that model is set up, the MDA content of given the test agent group and model control group compare, and difference has significance, judges this index positive as a result.1.5. liver homogenate reduced glutathion (GSH) assay method 1.5.1 principle
GSH and 5,5 '-two sulfur are reflected at nitro formic acid (DTNB) can generate xanchromatic 5-sulfo-2-nitro formic acid cation under the GSH-Px catalysis, in the 423nm wavelength maximum absorption band is arranged, and measures this ion concentration, can calculate the content of GSH.1.5.2 reagent
0.9% normal saline
4% sulfosalicylic acid solution
0.1mol/L PBS solution (pH=8.0)
Na
2HPO
4?13.452g
KH
2PO
4??0.722g
Adding distil water is to 1000ml
0.004%DTNB solution: take by weighing DTNB 40mg and be dissolved in the 0.1mol/L PBS solution (pH=8.0) of 1000ml.
Nitrine is received buffer
NaN
3??????16.25mg
EDTA-
Na2??7.44mg
Na
2HPO
4???1.732g
NaH
2PO
4???1.076g
Adding distil water is transferred pH7.0,4 ℃ of preservations to 1000ml with small amount of H Cl, NaOH.
Standard solution: take by weighing reduced form GSH15.4mg, add nitrine and receive buffer to 50ml, final concentration is a 1mmol/L1.5.3 method 1.5.3.1 sample determination: get liver 0.5g and add normal saline 5ml and fully grind to form screened stock (10% liver homogenate), get serosity 0.5ml behind the mixing and add 4% sulfosalicylic acid 0.5ml mixing, 3000rpm is centrifugal 10 minutes under the room temperature, gets supernatant and is sample.
Table 15
Measure the blank pipe of pipe
Sample 0.5ml-
4% sulfosalicylic acid-0.5ml
DTNB 4.5ml 4.5ml mixing, room temperature were placed after 10 minutes, and the 412nm place measures absorbance.1.5.3.2 standard curve
Table 16
12345 6Immol/L, (ml) 0 0.05 0.10 0.15 0.20 0.25 normal saline, (ml) 0.50 0.45 0.40 0.35 0.20 0.25DTNB, (ml) 4.50 4.50 4.50 4.50 4.50 4.50GSH amount, (μ mol/L) 0 100 200 300 400 5001.5.3.3 calculate
((μ mol/L) ÷ 50g/L1.5.4 date processing and result judge sample GSH content (μ mol/g hepatic tissue)=corresponding curve concentration value
The The data variance analysis, but the program of demanding party's difference analysis is carried out homogeneity test of variance earlier, and variance is neat, calculates the F value, F value＜F
0.05, conclusion: each organizes the mean differences does not have significance; The data of abnormal or heterogeneity of variance are carried out the conversion of suitable variable, wait to satisfy normal state or variance are neat require after, add up with the data after changing; If do not reach normal state or the neat purpose of variance yet after the variable conversion, use rank test instead and add up.
The result judges
Under the prerequisite that model is set up, the reduced form GSH content of given the test agent group and model control group compare, and difference has significance, judges this index positive as a result.1.6 triglyceride in the liver homogenate (TG) assay method 1.6.1 assay method: adopt the triglyceride content in triglyceride mensuration test kit (phosphoglycerol oxidase peroxidase method) mensuration 10% liver homogenate.Identical with the serum levels of triglyceride assay method, to operate by operating instruction with equivalent 10% liver homogenate alternative serum, measurement result is heavily represented with the mmol/g liver.1.6.2 date processing and result judge
The The data variance analysis, but need to carry out homogeneity test of variance earlier by the program of variance analysis, variance is neat, calculates the F value, F value＜F
0.05, conclusion: each organizes the mean differences does not have significance; F value 〉=F
0.05, P 〉=0.05 is added up with the comparative approach in twos of mean between a plurality of experimental grouies and matched group, and the data of abnormal or heterogeneity of variance are carried out suitable variable conversion, wait to satisfy normal state or variance are neat require after, add up with the data after changing; If do not reach normal state or the neat purpose of variance yet after the variable conversion, use rank test instead and add up.
The result judges
Under the prerequisite that model is set up, the TG of given the test agent group and model control group compare, and difference has significance, judges this index positive as a result.1.7 the hepatic pathology histology changes, diagnostic criteria and result judge the 1.7.1 experiment material: do the cross section from the leftlobe of liver middle part and draw materials, frozen section, soudan III dyeing.1.7.2 microscopy:, observe whole tissue slice continuously with 40 times of object lens from the pathological change that one of liver is looked closely wild opening entry cell.Main observation fat drops in distribution, scope and the area of liver.1.7.3 standards of grading
The hepatocyte lactone drips and is dispersed in, rare 0 minute
Contain the hepatocyte that fat drips and be no more than 1/4 1 fens
Contain the hepatocyte that fat drips and be no more than 1/2 2 fens
Contain the hepatocyte that fat drips and be no more than 3/4 3 fens
Hepatic tissue is almost dripped by fat and replaces 4 fens 1.7.4 date processing and result to judge
Adopt variance analysis, but need to carry out variance agent check earlier by the program of variance analysis, variance is neat, calculate the F value, F value＜F0.05, conclusion: each organizes the mean differences does not have significance: F value 〉=F0.05, and P≤0.05 is added up with the comparative approach in twos of mean between a plurality of experimental grouies and matched group; It is conversion that the data of abnormal or heterogeneity of variance are carried out suitable change, wait to satisfy normal state or variance are neat require after, add up with the data after changing; If do not reach normal state or the neat purpose of variance yet after the variable conversion, use rank test instead and add up.The result judges
Under the prerequisite that model is set up, between any one dosage group of model control group and given the test agent, steatosis alleviates, and the difference on the statistics is arranged, and can be judged as positive findings.1.8 the result judges: satisfy arbitrary condition, the decidable given the test agent has has auxiliary protection function 1.8.1 liver MDA, reduced form GSH and three of TG to detect the index positive as a result to alcoholic liver button internal affairs.1.8.2. wantonly two index positives and the histopathologic examination positive as a result in liver MDA, reduced form GSH and three indexs of TG.2. lipid peroxide catabolite malonaldehyde (MDA) in result's 2.1 liver homogenate
As shown in Table 17, the damage matched group is compared with negative control group, and MDA content obviously raises in the hepatic tissue, and difference has utmost point significance (P＜0.01); Tried each dosage group MDA content of thing and reduced, and utmost point significant difference (P＜0.01) is arranged than the damage matched group.Illustrate that being tried thing can reduce MDA content in the hepatic tissue.2.2 liver homogenate reduced glutathion (GSH)
As shown in Table 17, the damage matched group is compared GSH content with the feminine gender group and is obviously reduced, and difference has utmost point significance (P＜0.01).Tried each dosage group GSH content of thing and be higher than the damage matched group, difference has significance (P＜0.01).Illustrate and tried the exhaustion that thing can effectively stop GSH.2.3 triglyceride in the liver homogenate (TG)
As shown in Table 17, damage matched group and negative control compare, and liver TG content obviously raises, and difference has utmost point significance (P＜0.01).Tried each dosage group TG content of thing and be starkly lower than the damage matched group, difference has significance (P＜0.05).Illustrate and tried the content that thing can reduce TG in the liver.
Table 17 contains the compositions of dihydromyricetin and ampelopsin
Influence to malonaldehyde, reduced glutathion and triglyceride
2.4 hepatic pathology histological examination: get liver (Zuo Daye) 10% formalin fixed, the fat stains of frozen section soudan III, haematoxylin redyeing, mounting, microscopy the results are shown in Table 18.1) negative control treated animal: have 3 examples to see that slight steatosis appears in hepatocyte.2) damage control animals: the diffusivity steatosis all appears in hepatocyte, and fat drips and is classified as +++~ ++ ++ level.3) middle and high dosage group hepatic cell fattydegeneration degree is starkly lower than positive controls, and difference has significance (P＜0.05).Low dose group hepatic cell fattydegeneration degree and positive controls be there was no significant difference relatively.
| Group | Number of animals | MDA (μ mol/g liver is heavy) | GSH (μ mol/g liver is heavy) | TG (the mmol/g liver is heavy) | |||
| Meansigma methods | The P value | Meansigma methods | The P value | Meansigma methods | The P value | ||
| Matched group | ??10 | ??7.59±0.59 | ??0.000 | ??15.34±1.26 | ??0.000 | ??10.08±1.20 | ??0.000 |
| Model group | ??10 | ??17.08±2.30 | ??8.89±0.96 | ??50.94±1.22 | |||
| Low dose group | ??10 | ??11.25±1.34 | ??0.000 | ??11.95±0.99 | ??0.000 | ??38.32±2.75 | ??0.000 |
| Middle dosage group | ??10 | ??11.65±1.46 | ??0.000 | ??11.89±1.01 | ??0.000 | ??32.32±2.15 | ??0.000 |
| High dose group | ??10 | ??12.32±1.39 | ??0.001 | ??10.93±1.05 | ??0.000 | ??36.48±2.19 | ??0.000 |
Table 18 pair liver fat drips the influence of distribution
| Group (mg/kg) | Number of animals (only) | Total mark | The P value |
| Dosage (20) high dose (40) in negative control (0) damage contrast (0) low dosage (10) | ????10 ????10 ????10 ????10 ????10 | ????3 ????39## ????28 ????28* ????26* | ? ????＜0.01 ? ????＜0.05 ????＜0.05 |
Compare with negative control group: ##P＜0.01; Compare with the damage matched group: * P＜0.053.. conclusion: result of the test shows, first kind of compositions that embodiment 5 obtains can stop ethanol to cause liver liver GSH to exhaust effectively and MDA raises, alleviate hepatic cell fattydegeneration, have prevention ethanol liver damage function.Utilize first kind of compositions of second kind of compositions, embodiment 1 of embodiment 6, embodiment 5 and the third compositions of embodiment 2 to carry out above-mentioned identical test, obtained roughly the same result.Embodiment 10: the first kind of compositions that contains embodiment 5 be as 200 milliliters in the preparation Maotai of the Chinese liquor of additive, first kind of compositions 6.2g of embodiment 5,
Said components stirs, and obtains the liquid of clear, and it is the same with the Maotai of the first kind of compositions that does not add embodiment 5 to drink the sense of taste.Obtain identical result with embodiment 1 with 2 compositions respectively.Embodiment 11: the first kind of compositions that contains embodiment 5 gets 1000 milliliters of the preparation Erguotou wines of Chinese liquor as additive, first kind of compositions 53g of embodiment 5,
Said components stirs, and obtains the liquid of clear, and it is the same with the Erguotou wine of the first kind of compositions that does not add embodiment 5 to drink the sense of taste.Obtain identical result with embodiment 1 with 2 compositions respectively.Embodiment 12: the compositions that contains embodiment 2 is as 1000 milliliters of the preparation XIAOZAO wine of the fruit wine of additive, first kind of compositions 0.5g that embodiment 5 obtains,
Said components stirs, and obtains the natural colored liquid of former little jujube wine, and it is the same with the little jujube wine that does not add first kind of compositions that embodiment 5 obtains to drink the sense of taste.Obtain identical result with embodiment 1 with 5 compositions respectively.Embodiment 13: contain first kind of compositions that embodiment 5 obtains as 1000 milliliters in the preparation Maotai of the Chinese liquor of additive, and first kind of compositions 10g that embodiment 5 obtains,
Said components stirs, and obtains the liquid of clear, and it is the same with the Maotai that does not add first kind of compositions that embodiment 5 obtains to drink the sense of taste.Obtain identical result with embodiment 1 with 2 compositions respectively.Embodiment 14: contains first kind of compositions that embodiment 5 obtains and is mixed with 56 degree Chinese liquor 1000ml with medical alcohol and water, add first kind of compositions 0.5g that embodiment 5 obtains as the preparation of the Chinese liquor 1 of additive,
Said components stirs, and obtains the liquid of clear, and it is the same with the Erguotou wine that does not add first kind of compositions that embodiment 5 obtains to drink the sense of taste.Obtain identical result with embodiment 1 with 2 compositions respectively.Embodiment 15: contains first kind of compositions that embodiment 5 obtains and is mixed with 38 degree Chinese liquor 1000ml with medical alcohol and water, add first kind of compositions 1g that embodiment 5 obtains as the preparation of the Chinese liquor 2 of additive,
Said components stirs, and obtains the liquid of clear, and it is the same with the Erguotou wine that does not add first kind of compositions that embodiment 5 obtains to drink the sense of taste.Obtain identical result with embodiment 1 with 2 compositions respectively.Embodiment 16: contains first kind of compositions that embodiment 5 obtains and is mixed with 56 degree Chinese liquor 1000ml with medical alcohol and water, add first kind of compositions 2g that embodiment 5 obtains as the preparation of the Chinese liquor 3 of additive,
Said components stirs, and obtains the liquid of clear, and it is the same with the Erguotou wine that does not add first kind of compositions that embodiment 5 obtains to drink the sense of taste.Obtain identical result with embodiment 1 with 2 compositions respectively.Embodiment 17: the noodle preparation that contains compositions of the present invention is got first kind of compositions of oat flour 200g, Fagopyrum esculentum Moench 100g, tabernaemontanus bulrush bean flour 50g and embodiment 5 (or various compositionss of embodiment 1 or 2) 20g, and water is an amount of, mixes, and is pressed into noodles.Embodiment 18: contain the preparation wheat flour 300g of the bread of compositions of the present invention, dry yeast 3.5g, Saccharum Sinensis Roxb. 10g, salt 2g, warm water 200ml, perilla oil 12g, first kind of compositions of embodiment 5 (or various compositionss of embodiment 1 or 2) 25g, the mentioned component mixing is also smoked into bread.Embodiment 19: the preparation of beverage that contains compositions of the present invention is with dark plum natural juice 20ml, and water 200ml transfers and converts into plum beverage, adds first kind of compositions (or various compositionss of embodiment 1 or 2) of 50g embodiment 5, stirs, and obtains health beverage.It is an amount of to feed carbon dioxide in this beverage.
Claims (6)
1. compositions is characterised in that the dihydromyricetin that wherein contains 20% to 98% weight ratio and the ampelopsin of 2% to 80% weight ratio.
2. the compositions of claim 1 is characterised in that it also contains one or more and is selected from following composition: arbutin, gallic acid and/or tea polyphenols.
3. claim 1 or 2 compositions, be characterised in that wherein the content of arbutin is the 0-50wt% of dihydromyricetin and ampelopsin gross weight, the content of gallic acid is the 0-50wt% of dihydromyricetin and ampelopsin gross weight, and the content of tea polyphenols is the 0-50wt% of dihydromyricetin and ampelopsin gross weight.
4. a method for compositions for preparing one of claim 1 to 3 is characterised in that each monomer component is mixed in proportion.
5 one kinds of method for compositions that prepare one of claim 1 to 3 are characterised in that from ampelopsis and extract.
6. the preparation method of claim 4 is characterised in that wherein said ampelopsis comprises ampelopsis cantoniensis, a leaf beautiful Fructus Vitis viniferae, Ampelopsis grossedentata, Cayratia japonica (Thunb.) Gagnep., Radix Ampelopsis, Northeastern Caulis seu folium ampelopsis brevipedunculatae and Vitis Amurensis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031380549A CN100345539C (en) | 2003-05-30 | 2003-05-30 | Composition containing dihydro myricitrin and myricitrin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031380549A CN100345539C (en) | 2003-05-30 | 2003-05-30 | Composition containing dihydro myricitrin and myricitrin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1457775A true CN1457775A (en) | 2003-11-26 |
| CN100345539C CN100345539C (en) | 2007-10-31 |
Family
ID=29430713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031380549A Expired - Fee Related CN100345539C (en) | 2003-05-30 | 2003-05-30 | Composition containing dihydro myricitrin and myricitrin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100345539C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104015236A (en) * | 2014-06-17 | 2014-09-03 | 吉首大学 | Ampelopsis grossedentata extractive natural bamboo wood antiseptic agent and preparation method thereof |
| CN105232350A (en) * | 2015-11-05 | 2016-01-13 | 浙江中医药大学 | Water mask and making method thereof |
| CN107951881A (en) * | 2018-01-10 | 2018-04-24 | 青岛科技大学 | A kind of myricetin compound with synergy and preparation method thereof |
| CN111892566A (en) * | 2019-05-05 | 2020-11-06 | 首都医科大学 | Ampelopsis grossedentata water extract, preparation method thereof and application of water extract as acetylcholinesterase inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1393443A (en) * | 2001-06-29 | 2003-01-29 | 张友胜 | Process for preparing dihydromyricetin from porcelain ampelopsis |
| CN100345538C (en) * | 2003-05-30 | 2007-10-31 | 任启生 | Use of ampelopsin for preparing blood sugar reducing medicine |
-
2003
- 2003-05-30 CN CNB031380549A patent/CN100345539C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104015236A (en) * | 2014-06-17 | 2014-09-03 | 吉首大学 | Ampelopsis grossedentata extractive natural bamboo wood antiseptic agent and preparation method thereof |
| CN104015236B (en) * | 2014-06-17 | 2016-03-16 | 吉首大学 | A kind of Ampelopsis grossdentata (Hand.-Mazz.) W.T.Wang extract natural bamboo preservative and preparation method thereof |
| CN105232350A (en) * | 2015-11-05 | 2016-01-13 | 浙江中医药大学 | Water mask and making method thereof |
| CN105232350B (en) * | 2015-11-05 | 2018-03-23 | 浙江中医药大学 | Water surface film and preparation method thereof |
| CN107951881A (en) * | 2018-01-10 | 2018-04-24 | 青岛科技大学 | A kind of myricetin compound with synergy and preparation method thereof |
| CN111892566A (en) * | 2019-05-05 | 2020-11-06 | 首都医科大学 | Ampelopsis grossedentata water extract, preparation method thereof and application of water extract as acetylcholinesterase inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100345539C (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1268351C (en) | Sugar absorption inhibitors and process for producing the same | |
| CN1365283A (en) | Unfermented gel fraction from psyllium seed husks | |
| CN1876139A (en) | Medicinal preparation for treating children's fastidium, its preparation process and quality control method | |
| CN1348380A (en) | Herbal composition and medicament against diabetes mellitus type II manufactured thereof | |
| CN1836167A (en) | Diagnostic composition for diabetes type-2 and impaired glucose tolerance, and methods of use | |
| CN1288688A (en) | Composition containing original flower pigment and vitamin B6 derivative or its salt | |
| CN100345539C (en) | Composition containing dihydro myricitrin and myricitrin | |
| CN1917895A (en) | Extracts of houttuynia cordata and rubus coreanus and their composition for preventing and treating allergic diseases | |
| CN100341501C (en) | Health care food containing dihydromyricetin and myricetin composition | |
| CN1246011C (en) | Multi-function health care food and application thereof | |
| CN100344321C (en) | Medicinal composition, its preparation process and quality control method | |
| CN1911314A (en) | Plant extractive and its prepn. method | |
| CN1335161A (en) | Deer bone powder capsule | |
| CN100341416C (en) | Health food containing ampeloptin | |
| CN100345538C (en) | Use of ampelopsin for preparing blood sugar reducing medicine | |
| CN1304548C (en) | Health care wine containing dihydro-myricetin and myricetin composition | |
| CN1857588A (en) | Quality control method for Xianlinggubao preparation | |
| CN1291734C (en) | Method for preparing and controlling the quality of Chinese medicinal soft capsule | |
| CN108285827B (en) | Grape seed oil and preparation method thereof | |
| CN1730083A (en) | Yuanhe tablet and process for preparing the same | |
| CN1895347A (en) | Medicinal composition for treating infantile diarrhea and emesia | |
| CN1809284A (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress | |
| US11628194B2 (en) | Method of extracting active ingredients in mushrooms | |
| CN1289838A (en) | Wolfberry beer and its preparing process | |
| JP4251388B2 (en) | Method for producing fermented liquor containing anthocyan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071031 Termination date: 20210530 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |